


Third Preliminary Amendment  
 Serial No. 09/978,454  
 Page 9 of 9

030727.0027.CON1



VIII

wherein:

*D<sup>1</sup> cont'd*  
 Z' is selected from the group of -OH, -OC(O)R<sup>3</sup>, -OCO<sub>2</sub>R<sup>3</sup>, and -OC(O)SR<sup>3</sup>;

D<sup>4</sup> and D<sup>3</sup> are independently selected from the group of -H, alkyl, -OR<sup>2</sup>, -OH, and -OC(O)R<sup>3</sup>;  
 with the proviso that at least one of D<sup>4</sup> and D<sup>3</sup> are -H;

R<sup>2</sup> is selected from the group of R<sup>3</sup> and H;

R<sup>3</sup> is selected from the group of alkyl, aryl, alicyclic, and aralkyl;

wherein said compound of formula I is converted to MPO<sub>3</sub>H<sub>2</sub> by human liver microsomes, with  
 the proviso that MPO<sub>3</sub><sup>2-</sup> is not an FB Pase inhibitor;

and pharmaceutically acceptable prodrugs and salts of Formula VIII;

and a pharmaceutically acceptable excipient.--

### REMARKS

Claims 2-13 are pending. Upon the entry of this amendment, claims 2-19 will be pending.

Support for these new claims can be found throughout the specification, for instance at pp. 49-51 and p. 56.

Respectfully Submitted,

Date: 3/27/02

By: Jessica R. Wolff

Jessica R. Wolff  
 Reg. No. 37,261

Brobeck, Phleger & Harrison LLP  
 12390 El Camino Real  
 San Diego, CA 92130-2081  
 Direct Dial: (858)720-2500  
 Facsimile: (858)720-2555